000			02709nam a2200229 4500
003			PC6719
005			20180417112618.0
008			130622s2012 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aBernal González, Carmen _92130 _eEndocrinología y Nutrición
245	0	0	_aProlactinomas in men: a multicentre and retrospective analysis of treatment outcome. _h[artículo]
260			_c2012 _bClinical Endocrinology,
300			_a77(2):281-7.
500			_aFormato Vancouver: Iglesias P, Bernal C, Villabona C, Castro JC, Arrieta F, Díez JJ. Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome. Clin Endocrinol (Oxf). 2012 Aug;77(2):281-7.
501			_aPMID: 22288612
504			_aContiene 28 referencias
520			_aAIMS: To assess treatment outcome in male patients with micro- and macroprolactinomas. DESIGN: Multicentre and retrospective study. PATIENTS: Eighty-eight male patients (15 micro- and 73 macroprolactinomas), aged 40·3 ± 14·7 years, were studied. Time of follow-up ranged from 3 to 244 months. METHODS: Clinical, hormonal and radiological data were registered at diagnosis and follow-up. Treatment outcome was evaluated in relation to the modality of therapy (dopamine agonists, surgery and radiation therapy). RESULTS: Dopamine agonists normalized prolactin levels in 73·3% and 65·2% of patients with micro- and macroprolactinomas, respectively. Disappearance of tumour was reached in 53·3% and 28·3% of subjects with micro- and macroprolactinomas, respectively. Tumour absence at last visit was achieved in 7 of 14 patients with macroprolactinoma and treated by means of dual therapy (dopamine agonists and neurosurgery) and in 9 of 13 patients with macroprolactinoma managed with triple therapy (dopamine agonists, neurosurgery and radiation therapy). Normalization of prolactin levels at last visit was present in 68·9%, 79·6% and 69·2% of patients treated by medical therapy, dual therapy and triple therapy, respectively (differences not significant). Multivariate logistic regression analysis showed that the time on therapy was the only significant variable related to tumour disappearance. CONCLUSION: We conclude that medical therapy normalizes prolactin and reduces tumour size in the majority of men with prolactinomas. The addition of pituitary surgery with or without radiation therapy does not offer significant advantages over medical therapy with dopamine agonists in male patients with macroprolactinomas.
710			_9292 _aServicio de Endocrinología y Nutrición
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/6/pc6719.pdf _ySolicitar documento
942			_n0 _2ddc _cART
999			_c6719 _d6719